Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics-Reference-Cited by-同舟云学术

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics

Published:2011-08-15 Issue:10 Volume:32 Page:1303-1308
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Bae Jung-woo,Choi Chang-ik,Kim Mi-jeong,Oh Da-hee,Keum Seul-ki,Park Jung-in,Kim Bo-hye,Bang Hye-kyoung,Oh Sung-gon,Kang Byung-sung,Park Hyun-joo,Kim Hae-deun,Ha Ji-hey,Shin Hee-jung,Kim Young-hoon,Na Han-sung,Chung Myeon-woo,Jang Choon-gon,Lee Seok-yong

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.nature.com/articles/aps2011100.pdf

Reference36 articles.

1. Miners JO, Birkett DJ . Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525–38.

2. Schwarz UI . Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003; 33 Suppl 2: 23–30.

3. García-Martín E, Martínez C, Ladero JM, Agúndez JA . Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006; 10: 29–40.

4. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E . Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004; 50: 195–200.

5. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 60: 418–22.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes;Archives of Pharmacal Research;2023-12

2. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects;Archives of Pharmacal Research;2023-04-25

3. Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic‐pharmacodynamic model;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-01-13

4. Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population;Frontiers in Cardiovascular Medicine;2022-11-24

5. Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes;Archives of Pharmacal Research;2022-08